BioAtla Stock Forecast, Price & News

BioAtla (NASDAQ:BCAB) Frequently Asked Questions

Is BioAtla a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioAtla stock.
View analyst ratings for BioAtla or view top-rated stocks.

When is BioAtla's next earnings date?

BioAtla is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for BioAtla.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) released its earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.04.
View BioAtla's earnings history.

What price target have analysts set for BCAB?

5 analysts have issued 1-year price targets for BioAtla's shares. Their forecasts range from $49.00 to $87.00. On average, they anticipate BioAtla's share price to reach $65.20 in the next year. This suggests a possible upside of 188.5% from the stock's current price.
View analysts' price targets for BioAtla or view top-rated stocks among Wall Street analysts.

Who are BioAtla's key executives?

BioAtla's management team includes the following people:

• Dr. Jay M. Short, Co-Founder, CEO & Chairman (Age 63, Pay $1.06M)
• Mr. Scott Andrew Smith, Pres & Director (Age 59, Pay $824.51k) (LinkedIn Profile)
• Ms. Carolyn Anderson Short, Co-Founder, Exec. VP and Chief of Intellectual Property & Strategy (Age 56, Pay $859.2k)
• Mr. Richard A. Waldron, Chief Financial Officer (Age 67)
• Mr. Philippe Martin, Chief Clinical Devel. & Operations (Age 45)
• Lisa M. Pelton, Accounting Mang.
• Ms. Susie Melody, VP of HR
• Dr. Eric L. Sievers, Chief Medical Officer (Age 57) (LinkedIn Profile)
• Mr. Christian Vasquez, VP of Fin., Corp. Controller & Sec. (Age 46)

Who are some of BioAtla's key competitors?

Some companies that are related to BioAtla include SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Bavarian Nordic A/S (BVNRY), Relay Therapeutics (RLAY), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), Instil Bio (TIL), Allogene Therapeutics (ALLO), ImmunityBio (IBRX), BioCryst Pharmaceuticals (BCRX), Revolution Medicines (RVMD), Ginkgo Bioworks (DNA) and Editas Medicine (EDIT).
View all of BCAB's competitors.

When did BioAtla IPO?

(BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.78%), Janus Henderson Group PLC (5.12%), BlackRock Inc. (3.76%), Great Point Partners LLC (2.50%), Massachusetts Financial Services Co. MA (1.45%) and Deerfield Management Company L.P. Series C (1.37%). Company insiders that own BioAtla stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron and Scott Andrew Smith.
View institutional ownership trends for BioAtla.

Which institutional investors are selling BioAtla stock?

BCAB stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Deutsche Bank AG, Wellington Management Group LLP, Geode Capital Management LLC, Citigroup Inc., New York State Common Retirement Fund, and Alliancebernstein L.P.. Company insiders that have sold BioAtla company stock in the last year include Christian Vasquez, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, and Scott Andrew Smith.
View insider buying and selling activity for BioAtla or view top insider-selling stocks.

Which institutional investors are buying BioAtla stock?

BCAB stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Janus Henderson Group PLC, Suvretta Capital Management LLC, Candriam Luxembourg S.C.A., Morgan Stanley, Deerfield Management Company L.P. Series C, Sphera Funds Management LTD., and BlackRock Inc.. Company insiders that have bought BioAtla stock in the last two years include Cormorant Asset Management, Lp, and Guy Levy.
View insider buying and selling activity for BioAtla or or view top insider-buying stocks.

How do I buy shares of BioAtla?

Shares of BCAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $22.60.

How much money does BioAtla make?

BioAtla has a market capitalization of $832.49 million and generates $430 thousand in revenue each year.

How many employees does BioAtla have?

BioAtla employs 36 workers across the globe.

What is BioAtla's official website?

The official website for BioAtla is www.bioatla.com.

How can I contact BioAtla?

The company can be reached via email at [email protected].